Brief: Evelo Biosciences Reports New Positive Confirmatory Data From Phase 1B Trial Of EDP1815 In Atopic Dermatitis
20/01/2021 12:05
Jan 20 (Reuters) - Evelo Biosciences Inc EVLO.O :
* EVELO BIOSCIENCES REPORTS NEW POSITIVE CONFIRMATORY DATA
FROM
PHASE 1B TRIAL OF EDP1815 IN ATOPIC DERMATITIS
* EVELO BIOSCIENCES INC - EDP1815 WAS WELL TOLERATED, AND
SHOWED
CLINICALLY MEANINGFUL AND CONSISTENT CHANGES IN ALL MEASURED
PHYSICIAN-REPORTED OUTCOMES
Source text for Eikon: ID:nGNX91LJGJ
Further company coverage: EVLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evelo Biosciences
See all newsU.S. RESEARCH ROUNDUP- Evelo Biosciences, Nkarta, O'Reilly Automotive
U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Evelo Bio slumps after skin disease drug fails in mid-stage study
U.S. STOCKS ON THE MOVE-Nvidia, Westlake, North American steel companies
U.S. STOCKS ON THE MOVE-TMC, PayPal, TOMI